PHIO: Phio Pharmaceuticals Corp. Stock

by  •  • Comments Off on PHIO: Phio Pharmaceuticals Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 13.04
Enterprise Value ($M) 7.52
Book Value ($M) 4.72
Book Value / Share 0.99
Price / Book 2.76
NCAV ($M) 4.72
NCAV / Share 0.99
Price / NCAV 2.76

Profitability (mra)
Return on Invested Capital (ROIC) -1.51
Return on Assets (ROA) -1.04
Return on Equity (ROE) -1.28

Liquidity (mrq)
Quick Ratio 5.65
Current Ratio 5.65

Balance Sheet (mrq) ($M)
Current Assets 5.74
Assets 5.74
Liabilities 1.01
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -7.39
Net Income -7.15
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -7.11
Cash from Investing 0.01
Cash from Financing 4.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-07 13G/A CVI Investments, Inc. 4.90
01-23 13G Orca Capital AG 9.90
01-17 13G Intracoastal Capital, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 528,184 1,497,266 35.28
2025-04-16 873,953 2,334,797 37.43
2025-04-15 1,644,219 4,353,251 37.77

(click for more detail)

Similar Companies
PASG – Passage Bio, Inc. PCSA – Processa Pharmaceuticals, Inc.
PDSB – PDS Biotechnology Corporation PLUR – Pluri Inc.
PMCB – PharmaCyte Biotech, Inc.


Financial data and stock pages provided by
Fintel.io